• Publications
  • Influence
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3
TLDR
The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on standard treatments.
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
TLDR
This phase 3 study investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
TLDR
With the present development of various new anticancer agents, it is recommended that alternative formulation approaches should be pursued to allow a better control of the toxicity of the treatment and the pharmacological interactions related to the use of CrEL.
The clinical approach towards chondrosarcoma.
TLDR
In low-grade chondrosarcoma confined to the bone, extensive intralesional curettage followed by local adjuvant treatment and filling the cavity with bone graft has promising long-term clinical results and satisfactory local control.
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
TLDR
This phase 3 randomised controlled trial assessed whether dose intensification of doxorubicin with ifosfamide improves survival of patients with advanced soft-tissue sarcoma compared with doxorbicin alone.
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
TLDR
Overall survival was improved in patients assigned to eribulin compared with those assigned to an active control, suggesting that eriboxin could be a treatment option for advanced soft-tissue sarcoma.
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
TLDR
This work presents a meta-analyses of the prophylactic and descriptive literature reviews that show clear trends in prognosis and in particular in women diagnosed with breast cancer with atypical adrenal gland prolapse preoperatively and after treatment with chemotherapy.
Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
TLDR
Genetic polymorphisms in three genes involved in sunitinib pharmacokinetics are associated with PFS in mRCC patients treated with this drug, and the findings advocate prospective validation and further elucidation of these genetic determinants in relation to sunit inib exposure and efficacy.
Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.
TLDR
Findings of recent investigations on the associations of SNPs and clinical outcome after oxaliplatin chemotherapy in metastatic colorectal cancer are covered.
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
TLDR
Osteosarcoma and Ewing sarcoma have a relatively high incidence in the second decade of life, while chondrosarcomas are more common in older age groups, and chordomas are rare; arising with an incidence of ∼0.5/ million population per year.
...
1
2
3
4
5
...